|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Rationale:</b> It has been reported that peroxisome proliferator activated receptor γ (PPARγ) level decreases significantly in the brains of Alzheimer's disease (AD) patients and mice models, while the mechanism is unclear.
|
30128052 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PPARgamma polymorphism did not influence the risk of AD.
|
15666037 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARgamma agonists have been shown to be efficacious in animal models of Alzheimer's disease, stroke, multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis.
|
16766086 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model.
|
27791018 |
2016 |
|
Alzheimer's Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
|
28522250 |
2017 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PPARγ activator rosiglitazone (RSZ) or AMPK activator AICAR increased the expression level of IDE and decreased Aβ levels in mice with AD and T2D.
|
29222348 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.
|
30271148 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR<i>γ</i>) agonists such as rosiglitazone and pioglitazone reduce amyloid and tau pathologies, inhibit neuroinflammation, and improve memory impairments in several rodent models and in humans with mild-to-moderate AD.
|
30420872 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects.
|
20733306 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the different classes of diabetic drugs, pioglitazone (PIO), a PPARγ agonist classed as an insulin sensitizer, is of the highest interest for AD management.
|
30738020 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a transcription factor binding site of the BACE1 promoter, peroxisome proliferator-activated receptor-γ (PPARγ) response element regulates the activity of the BACE1 promoter activity, indicating that PPARγ may become a potential target for Alzheimer's disease treatment.
|
22166376 |
2012 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on these findings, the gene encoding PPARgamma can be viewed as an interesting candidate in AD.
|
16988505 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.
|
17440948 |
2007 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CBD suppresses, through activation of PPARγ, pro-inflammatory signaling and may be a potential new candidate for AD therapy.
|
28981597 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical studies suggest that agonists at peroxisome proliferator-activated receptor gamma (PPARgamma) may exert beneficial effects in patients with mild-to-moderate Alzheimer's disease (AD), but the mechanism for the potential therapeutic interest of this class of drugs has not yet been elucidated.
|
20336061 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARgamma) suggest an improvement of cognitive function in Alzheimer's disease (AD) patients.
|
19109927 |
2009 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Donepezil is a first-line acetylcholinesterase inhibitor used for the treatment of AD that has been found, in addition to its potent acetylcholinesterase inhibitory effect, to act through other non-cholinergic mechanisms such as affecting mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator (PGC1α).
|
29852870 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, these three bioactive lipids (resolvin E1, neuroprotectin D1 and hydroxy-linoleic acid) may be favourably considered as ideal drug candidates in therapeutic modulation of clinical conditions such as type 2 DM, Alzheimer's disease and other instances where PPARγ is a key player.
|
28109294 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we analyzed the expression levels of CX3CL1, TREM2, and PPARγ in tissue homogenates from human brain regions that have different degrees of vulnerability to neuropathological AD-related changes to obtain insights into the pathogenesis and progression of AD.
|
25596843 |
2015 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, the efficacy of these agents in inhibiting a broad range of inflammatory responses suggests PPARgamma agonists may provide a novel therapeutic approach to AD.
|
10632585 |
2000 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In a replication study, we confirmed significant association of SNPs within three genes--PPARgamma, SOS2, and PCK1--with Alzheimer's disease.
|
17440948 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In previous studies, we have demonstrated the beneficial effects of classic PPARγ agonists on neuroprotection against Aβ oligomer neurotoxicity in a double transgenic mouse model of Alzheimer' disease (AD).
|
28655613 |
2017 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In summary, the present meta-analysis suggests that the PPAR-γ rs1801282 polymorphism may not be associated with genetic susceptibility of AD in general population.
|
25770052 |
2015 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we have shed some light on the recent progress of how, PPARγ agonist selectively modulated different cellular targets in AD and its amazing potential in the treatment of AD.
|
30152284 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of PPARγ degradation and PERK/eIF2α phosphorylation are involved in the course, therefore suggesting that ICS II might be a promising potential compound for the treatment of AD.
|
28337142 |
2017 |